Viral samples collected from dozens of covid patients suggest that Merck & Co.’s new anti-viral covid drug Lagevrio (molnupiravir) is triggering the formation of new “strains” of the disease. A preprint study compiled by researchers from the U.S.-based Francis Crick Institute and Imperial College London explains that the drug-linked mutations of the so-called “virus” are not necessarily...